Can European biotechs achieve greater scale in a fragmented landscape?

McKinsey & Company

World-class science and innovation need to be matched with stronger scale-up capabilities and a broader funding base if Europe is to emerge as a leader in biotech.

A new portfolio model for biotech

McKinsey & Company

An emerging model for biotech companies could disrupt the R&D landscape and open up new ways to invest, motivate teams, and shape the innovation pipeline.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Frost & Sullivan

As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies.”

What’s ahead for biotech: Another wave or low tide?

McKinsey & Company

Even in tough times, investor expectations and deal making in biotech are surging. Can the sector maintain its strong growth? Insights on Pharmaceuticals & Medical Products Venture capital Biotechnology

Infographic: Biotech hot spots in a fragmented European landscape

McKinsey & Company

We mapped out 1,382 biotechs based in Europe and some interesting themes emerged. Insights on Pharmaceuticals & Medical Products Biotechnology

The committed innovator: A conversation with Neal Gutterson of Corteva

McKinsey & Company

How a biotech scientist helped transform a traditional science organization into an innovation leader. Strategy & Corporate Finance Insights

Where is the Reporting Line for an Alliance Team?

Peter Simoons

This is what we most often see in pharma and biotech alliances. Last week I was asked a question about where would be the best location for an alliance & partnerships team in an organisation for reporting purposes.

Manager, Analyst & Investor Relations

LaVoie Health Science Blog

Knowledge and understanding of what drives value for biotech, platform and product companies in health as well as knowledge of the specialist investors, banks, analysts. Seeking an individual that wants to join a growing team of health and science communications experts to drive investor targeting and outreach as well as handling of investor meetings with senior management at client companies. Track investor outreach, report and guide on next steps based on feedback.

LHS Expert Insights: ESG Issues for Life Science Innovators

LaVoie Health Science Blog

As investments into sustainable companies and funds have surged to new highs, how can biotech and life science companies best position themselves with this burgeoning group of investors. Interviews with our senior practice managers about issues of important to life science innovators.

A Well-Honed Message Will Give You the Edge You Need

LaVoie Health Science Blog

At the same time, the biotech and pharmaceutical industries are in the spotlight as never before as nations and companies push programs to try to develop vaccines and therapeutics for the virus faster than drugs have ever been created before.

Intern

LaVoie Health Science Blog

LaVoieHealthScience interns work with an innovative account team on key pharma and biotech accounts as well as assisting with agency marketing efforts. Our interns grow professionally through exposure to a wide range of corporate marketing and communications, media relations and investor relations accounts and projects.

AVP/VP, PR & Media

LaVoie Health Science Blog

The ideal experience is in Biotech, Pharma, Device, MedTech, Public Health & Wellness and will contribute to agency revenue growth by retaining and organically growing the existing portfolio of clients, as well as leveraging his/her relationships and deep experience as a healthcare industry leader, to attract new clients through relationship cultivation and network development.

Mike Gaito, Global Head of Healthcare Investment Banking at J.P. Morgan talks #JPM21 going virtual, IPOs, and broader market trends for the new year

LaVoie Health Science Blog

Wainwright has announced their “Bioconnect” event will be held virtually during the same week as JPM, and the Biotech Showcase, traditionally held at the Hilton in San Francisco, is piloting a new virtual format with advance access for participants beginning as early as this November.

Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®

Frost & Sullivan

Based on its recent analysis of the North American market for industrial enterprise performance management, Frost & Sullivan recognizes Pharmactive Biotech Products, S.L. About Pharmactive Biotech Products, S.L. Pharmactive Biotech Products, S.L.,

5 Virtual Success Tips for Sales and Marketing Leaders

CoSell Blog

Just a few days ago, Pfizer and Biotech announced they are making headway on a vaccine that could be released by spring. As business leaders, we’re always on the lookout for success insights.

Ep. 163 – SADA Systems COO, Dana Berg

COO Alliance

Our guest today is COO Alliance Member, Dana Berg the COO of SADA Systems. . As Chief Operating Officer, Dana Berg is driven by the singular mission of identifying and implementing innovative solutions that create competitive advantages for our customers.

7 Reasons Why PPD’s Acquisition will Help TMO Gain a Top Spot in the CRO Market

Frost & Sullivan

The expanded portfolio will help build long-term relationships with small and mid-sized pharma and biotech sponsors due to increased engagement early on in the drug development process.

Watch: AI and the Future of Work Webinar

Partnership on AI

Watch the webinar as the assembled team of experts discuss cut through common misconceptions and highlight findings from case studies featuring three different organizations integrating AI from three different sectors (Steel, Retail Banking, and Biotech). What are the real-world impacts of AI on labor and the economy?

Is the Potential Threat of Shareholder Activism Heightened by the Pandemic?

LaVoie Health Science Blog

Elliott noted that there was a global opportunity now for potential acquisitions in biotech and pharmaceuticals, given the high hopes and intense demands created by the pandemic. And is your company prepared for what may be coming next?

Tergus Lauded by Frost & Sullivan for Its Full-spectrum CRO Services for Therapeutics in Dermatology

Frost & Sullivan

The company works with customers across business verticals such as generics and novel drugs, driven mainly by large pharma, specialty pharma, and biotech startups.

Why nano-capitalization public companies should evaluate strategic alternatives, including going private transactions

The Capital Alliance Blog

It might make sense for a biotech company, for example, that is researching a new drug and needs ready access to capital. By Russell Tolander. Managing Director. Nano-capitalization public companies, those with a valuation of less than $50 million, have fewer active buyers interested in them in today’s public markets, due to existing trends such as investors’ favoritism toward large companies, technology startups and disruptive or innovative business models (think Uber, Lyft, Amazon).

New Partners To Strengthen Global Community of Practice

Partnership on AI

By placing philosophers and artists in key research sites to foster dialogue with technologists, the aim of the program is to render AI and Biotech visible as unusually potent experimental sites for reformulating our vocabulary for thinking about ourselves. Central to our ability to produce unique research is the diversity of our “community of practice.”